The Genetics of Smith-Magenis Syndrome

Understanding the genetics of Smith-Magenis Syndrome (SMS) is like looking at a blueprint to see why a building was constructed a certain way. At its core, SMS is caused by having only one working copy of a specific gene called RAI1 (Retinoic Acid Induced 1) instead of the usual two ^[1][2]. This is known as haploinsufficiency—where a single “dose” of the gene is not enough for the body to function correctly ^[3].

The Role of the RAI1 Gene

The RAI1 gene produces a protein that lives in the cell’s nucleus and tells other genes how and when to work ^[3]. It is especially active in the brain, where it helps with neuronal communication, regulating the body’s internal clock (circadian rhythms), and metabolism ^[4][5][6]. When there isn’t enough RAI1 protein, these systems don’t run smoothly.

Two Genetic Subtypes

There are two main ways the RAI1 gene can be affected. While these subtypes show group-level trends in research cohorts, they do not strictly predict your individual child’s future. There is substantial overlap between the groups, and your child’s own developmental assessment should always guide their care ^[7].

1. 17p11.2 Deletion (Approx. 90% of cases)

In this version, a small piece of chromosome 17 is missing entirely ^[1]. This missing piece always includes the RAI1 gene, but it usually takes several “neighbor” genes with it ^[2].

• Cognition and Behavior: Group-level data suggests children with deletions tend to have a higher burden of intellectual disability compared to those with variants ^[8]. They may also show more “externalizing” behaviors, such as physical aggression or impulsivity ^[7].
• Physical Features: Deletion-related SMS is more likely to include multisystem physical findings, such as scoliosis, hearing loss, and heart or kidney concerns ^[9][10].

2. RAI1 Pathogenic Variant (Approx. 10% of cases)

In these cases, the chromosome is intact, but there is a “spelling error” (a pathogenic variant) within the RAI1 gene itself that stops it from working properly ^[11]. Note that a “variant of uncertain significance” (VUS) does not confirm an SMS diagnosis; it must be classified as pathogenic or likely pathogenic based on the clinical picture.

• Cognition and Behavior: On average, children in this group often have slightly higher cognitive scores ^[8]. Their behavioral patterns may be more “internalizing,” meaning they might experience more anxiety, social withdrawal, or depressed mood ^[7][8].
• Weight: Some evidence suggests that early-onset obesity may be more frequent in the variant group ^[2][12].

The Importance of the FLCN Gene

When a child has a 17p11.2 deletion, it is critical to check the genetic report to see if a neighboring gene called FLCN was also lost. The FLCN gene helps protect the body against certain types of tumors ^[13].

If the FLCN gene is deleted, it can cause a condition similar to Birt-Hogg-Dubé (BHD) syndrome ^[14]. While rare, this increases the risk for non-cancerous skin bumps and a specific type of kidney cancer later in life. Because of this, medical experts recommend that individuals with a deletion involving FLCN receive specialist genetic and urologic counseling ^[13]. A BHD-oriented surveillance plan typically involves lifelong kidney imaging (often repeated MRIs, as ultrasounds can miss small lesions) starting in adulthood ^[15]. Do not attempt to arrange this imaging on your own—always work with a specialist to determine the appropriate modality and interval.

Confirming the Subtype: Testing Methods

Testing strategy depends on the patient’s phenotype. A genetics team may use:

• Chromosomal Microarray (CMA) or Deletion/Duplication Analysis: Often used first to scan the chromosomes and find missing pieces (deletions) ^[16].
• Gene Sequencing (Multigene panels or Exome/Genome testing): If a microarray is normal but SMS is suspected, sequencing looks for pathogenic variants within the RAI1 gene itself ^[17][18].

Your Genetic Report Checklist

When you review your child’s lab results with a geneticist, ensure you can answer these specific questions:

1. Is it a deletion or a pathogenic variant? ^[1].
2. What are the exact coordinates? (e.g., “chr17:16,000,000-19,000,000”) ^[7].
3. Is the FLCN gene included in the deletion? (This determines if specialist BHD-tumor surveillance is needed later in life) ^[13].
4. Have parents been tested? (To confirm recurrence risks).